Literature DB >> 15373684

DNA analysis for donor screening of Dombrock blood group antigens.

J R Storry1, C M Westhoff, D Charles-Pierre, M Rios, K Hue-Roye, S Vege, S Nance, M E Reid.   

Abstract

Due to the scarcity of reliable antibodies, RBC typing for Doa and Dob is notoriously difficult. Inaccurate typing can place patients at risk for hemolytic transfusion reactions. The molecular basis of the DOA/DOB polymorphism is associated with three nucleotide changes:378 C>T, 624 T>C,and 793 A>G of DO. While the 378 C>T and 624 T>C are silent mutations, the 793A>G polymorphism in codon 265 encodes asparagine for Doa and aspartic acid for Dob. We describe here the use of a PCR-RFLP assay as an alternative to traditional hemagglutination for typing donor blood for Dombrock. Primers were designed to amplify the region of DO containing the 793A>G polymorphism. DNA samples from blood donors were amplified and subjected to RFLP analysis. A total of 613 samples were tested for the Dombrock polymorphism (793 A>G) by PCRRFLP. PCR-RFLP can be used to screen for Do(a-) or Do(b-) donors. This approach overcomes the scarcity of the reagents required for testing by hemagglutination.

Entities:  

Year:  2003        PMID: 15373684

Source DB:  PubMed          Journal:  Immunohematology        ISSN: 0894-203X


  3 in total

1.  Screening Donors for Rare Antigen Constellations.

Authors:  Franz F Wagner
Journal:  Transfus Med Hemother       Date:  2009-05-26       Impact factor: 3.747

2.  A PCR-based strategy for Dombrock screening in Brazilian blood donors reveals a novel allele: the DO* A-WL.

Authors:  Wilson Baleotti; Rodrigo Buzinaro Suzuki; Milena Polotto; Marcelo Ortega Ruiz; Antonio Fabron; Lilian Castilho
Journal:  J Clin Lab Anal       Date:  2011       Impact factor: 2.352

Review 3.  Transfusion Medicine and Molecular Genetic Methods.

Authors:  Rozieyati Mohamed Saleh; Zulkafli Zefarina; Nor Fazila Che Mat; Geoffrey Keith Chambers; Hisham Atan Edinur
Journal:  Int J Prev Med       Date:  2018-05-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.